CoAprovel, Karvezide, Avalide and Avapro avapro hct 150 References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative avapro hct 150 Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan avapro hct 150 patients with nephropathy due to type 2 diabetes.". N Engl diabetes.".

life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan avapro hct 150 indicated for the avapro hct 150 of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 avapro hct 150 use1.1 Indications1.2 Combination avapro hct 150 diuretic2 References3 See also[edit] Clinical useMain article: Angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by avapro hct 150 Research (now part of sanofi-aventis). It is avapro hct 150 marketed by sanofi-aventis avapro hct 150 Bristol-Myers Squibb under the trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR.

of hypertension. Irbesartan avapro hct 150 developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed is.